355.97MMarket Cap-1.78P/E (TTM)
3.510High3.380Low2.30MVolume3.490Open3.470Pre Close7.84MTurnover2.40%Turnover RatioLossP/E (Static)104.39MShares7.56052wk High-2.18P/B327.12MFloat Cap2.30052wk Low--Dividend TTM95.93MShs Float42.410Historical High--Div YieldTTM3.75%Amplitude2.300Historical Low3.405Avg Price1Lot Size
Revance Therapeutics Stock Forum
Dow Jones· 1 min ago
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
Monday, 6th January at 9:00 am
Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories
GENEVA, Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (NASDAQ: RVNC) to acquire Revance for $3.60 per s...
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
No comment yet